芬兰乙型肝炎感染流行病学:对免疫策略的启示
该研究分析芬兰2004-2012年报告的急性和慢性乙型肝炎病例,估计急性感染发病率、慢性感染发生率及移民相关慢性携带者流入。校正无症状感染后急性乙型肝炎估计发病率为1.67/10万/年(95% Crl 1.43-1.94),是登记发病率的4.2倍。研究估计每年7例新慢性感染由国内获得性感染引起,仅占慢性感染总发病率的1.2%,其中每年约3例可通过普遍婴儿疫苗接种预防。作者认为国内获得性慢性乙型肝炎感染有限,绝大多数慢性感染发生在外国出生人群中,因此普遍婴儿免疫规划在芬兰可预防的慢性感染数量有限。
要点
- 校正无症状感染后,芬兰急性乙型肝炎估计发病率为1.67/10万/年(95% Crl 1.43-1.94)。
- 急性与慢性乙型肝炎感染的估计终生风险分别为0.13%和0.01%。
- 每年7例新慢性感染由国内获得性感染引起,占慢性感染总发病率的1.2%。
核心结论
- 由于新生儿和儿童乙型肝炎感染罕见,国内获得性感染导致的慢性乙型肝炎感染数量非常有限。
- 绝大多数慢性乙型肝炎感染发生在外国出生人群中,因此无法通过芬兰的普遍婴儿免疫规划预防。
- 即使采用针对性免疫规划,乙型肝炎感染发病率仍保持较低水平。
研究设计与样本
- 分析2004-2012年报告至国家传染病登记处的乙型肝炎病例,并使用预先开发的方法校正急性无症状感染。
- 通过将年龄别慢性感染风险应用于估计的急性感染发病率,估计慢性感染的预测发病率。
- 利用2004-2012年移民数据和WHO区域携带率估计,估计移民相关的慢性携带者流入。
主要发现
- 校正无症状感染后,芬兰急性乙型肝炎估计发病率为1.67/10万/年(95% Crl 1.43-1.94),是登记发病率的4.2倍。
- 急性乙型肝炎和慢性乙型肝炎的估计终生风险分别为0.13%和0.01%。
- 估计每年有7例新慢性感染由芬兰境内获得的感染引起,这些新慢性感染占慢性感染总发病率的1.2%。
- 估计最终每年有3例慢性感染可能通过普遍婴儿疫苗接种规划预防。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We describe the current epidemiology of acute and chronic hepatitis B infections in Finland. We estimate the total incidence of chronic hepatitis B following from the current incidence of acute infections and the influx of chronic carriers of hepatitis B associated with net immigration. We evaluate the incidence of hepatitis B infections preventable by a universal vaccination programme among infants. METHODS: We analysed hepatitis B cases reported to the National Infectious Disease Register during 2004-2012 and used pre-developed methods to adjust for acute asymptomatic infections. We estimated the projected incidence of chronic infection by applying age-specific risks of chronic infection to the estimated incidence of acute infection. We estimated the influx of chronic carriers associated with immigration by utilising data on immigration during 2004-2012 and the WHO regional estimates of carriage prevalence. RESULTS: The estimated incidence of acute hepatitis B infection in Finland, adjusted for asymptomatic infections, was 1.67 per 100,000 per year (95% Crl 1.43-1.94) which is 4.2-fold to the register-based incidence. The estimated lifetime risks of acute and chronic hepatitis B infections were 0.13% and 0.01%, respectively. We estimated that annually seven new chronic infections would result from infections acquired in Finland. These new chronic infections accounted for 1.2% of the total incidence of chronic infections. We estimated that eventually three chronic infections per year would be potentially preventable by a universal infant vaccination programme. CONCLUSIONS: Partly due to the fact that hepatitis B infections in neonates and in children are rare, a very limited number of chronic hepatitis B infections resulted from infection acquired within the country. A vast majority of chronic hepatitis B infections occurred among foreign-born persons and were therefore not preventable by a universal infant immunisation programme in Finland. Even with a targeted immunisation programme, the incidence of hepatitis B infection has remained low.
引用
- Karvonen T, Auranen K, Kuusi M, et al. Epidemiology of hepatitis B infection in Finland: Implications for immunisation policy. Vaccine. 2016. PMID: 28003042. doi:10.1016/j.vaccine.2016.11.090
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。